摘要
Invariant natural killer T(iNKT)cells are good candidates for antitumor immunotherapies due to their functional advantages and low toxicity.Their promising utility has been exhibited by studies in animal models and clinical trials.Here,we discuss the strategies and challenges of iNKT cell-based immunotherapies.
基金
supported by National Natural Science Foundation of China grants 91942310,81801548,81771671,and 91954122
National Key R&D Program of China grant 2017YFA0505300
the Fundamental Research Funds for the Central Universities(WK2070000134).
